AI Pathology Quality Control Market Report 2026

The artificial intelligence (AI) pathology quality control market size has grown exponentially in recent years. It will grow from $1.78 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 21.4%. The growth in the historic period can be attributed to increasing pathology workload volumes, early digitization of pathology slides, growing complexity of cancer diagnostics, demand for standardized reporting, initial adoption of ai-assisted pathology tools.

The artificial intelligence (AI) pathology quality control market size is expected to see exponential growth in the next few years. It will grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to increasing investments in digital pathology platforms, rising demand for precision diagnostics, expansion of ai validation in clinical workflows, growing integration of pathology data analytics, increasing regulatory emphasis on diagnostic quality control. Major trends in the forecast period include increasing deployment of AI-based slide quality assessment, rising adoption of automated error detection tools, growing standardization of pathology workflows, expansion of digital pathology integration, enhanced focus on diagnostic accuracy assurance.

The growing demand for personalized medicine is expected to drive the growth of the artificial intelligence (AI) pathology quality control market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies based on an individual’s genetic makeup, lifestyle, and environment. Its rising adoption is largely driven by advances in genomics, which allow precise identification of genetic variations and enable tailored treatments for patients. AI pathology quality control supports personalized medicine by providing accurate and consistent diagnostic insights, facilitating individualized treatment plans. It helps reduce diagnostic errors through automated quality checks, enhancing accuracy and reliability, and ultimately promoting patient-specific care. For example, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Therefore, the increasing demand for personalized medicine is expected to propel the AI pathology quality control market.

Leading companies in the AI pathology quality control market are focusing on developing advanced solutions that enhance diagnostic accuracy, streamline laboratory workflows, and ensure the reliability of pathology data. Advanced AI-powered solutions use next-generation artificial intelligence technologies to perform complex tasks with greater precision, speed, and efficiency. For instance, in November 2023, PathAI, a US-based biotechnology firm, launched ArtifactDetect 1 on its AISight digital pathology platform. The tool automates the detection and quantification of artifacts in whole slide images (WSI), which are irrelevant morphological features that can affect diagnostic accuracy. ArtifactDetect reduces misdiagnosis and the need for rescans by pre-screening slides for quality issues, improving accuracy, laboratory efficiency, and overall throughput. This innovation supports timely corrective measures, such as re-staining or re-scanning, ultimately enhancing the digital pathology workflow and conserving resources for technicians and pathologists.

In November 2024, Molbio Diagnostics Pvt. Ltd., an India-based molecular diagnostics company, acquired a majority stake in OptraSCAN Inc. through a $30 million investment. Through this acquisition, Molbio aims to strengthen its presence in digital and AI-driven pathology, expand its diagnostic portfolio beyond molecular testing, enhance global market reach, and accelerate innovation in pathology quality control and precision diagnostics. OptraSCAN Inc., based in the US, provides AI solutions for pathology quality control as part of its digital pathology offerings.

Major companies operating in the artificial intelligence (AI) pathology quality control market are Roche Diagnostics GmbH, Danaher Corporation, Philips Healthcare, Agilent Technologies Inc., Hologic Inc., Clinisys Group Ltd., Sectra AB, PathAI Inc., OptraSCAN Inc., Paige.AI Inc., Proscia Inc., Quibim S.L., 3DHISTECH Ltd., Visiopharm A/S, Indica Labs Inc., Ibex Medical Analytics Ltd., Aiosyn B.V., DeepBio Inc., Nucleai Ltd., Gestalt Diagnostics LLC.

North America was the largest region in the artificial intelligence (AI) pathology quality control market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) pathology quality control market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) pathology quality control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the AI pathology quality control market by increasing costs of imported digital scanners, high-performance servers, data storage systems, and specialized imaging hardware. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported pathology equipment, while Asia-Pacific faces higher costs for export-oriented hardware manufacturing. These tariffs are increasing capital expenditure and slowing technology upgrades. At the same time, they are supporting domestic manufacturing of pathology hardware, local software innovation, and regional deployment of cloud-based AI quality control solutions.

The artificial intelligence (AI) pathology quality control market research report is one of a series of new reports that provides artificial intelligence (AI) pathology quality control market statistics, including artificial intelligence (AI) pathology quality control industry global market size, regional shares, competitors with a artificial intelligence (AI) pathology quality control market share, detailed artificial intelligence (AI) pathology quality control market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) pathology quality control industry. This artificial intelligence (AI) pathology quality control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) pathology quality control involves the use of AI algorithms and machine learning models to automatically evaluate and ensure the accuracy, consistency, and reliability of pathology data and slide interpretations. Its main goal is to identify errors, standardize analyses, and improve diagnostic precision in histopathology and cytopathology workflows, ultimately contributing to better patient outcomes.

The key components of AI pathology quality control include software, hardware, and services. Software encompasses AI-powered platforms and applications designed for automated analysis, quality assessment, and error detection within pathology workflows. These solutions can be implemented via cloud-based or on-premises systems. They are applied in areas such as cancer diagnostics, infectious disease diagnostics, digital pathology, and research, and serve important end-users including hospitals, diagnostic laboratories, research institutes, and pharmaceutical and biotechnology companies.

The artificial intelligence (AI) pathology quality control market consists of revenues earned by entities by providing services such as automated slide review, error detection in pathology reports, consistency checks in histopathology and cytopathology analyses, digital image analysis, workflow optimization, and validation of diagnostic results using AI-powered tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) pathology quality control market also includes sales of artificial intelligence (AI)-powered pathology software, digital pathology platforms, image analysis tools, and quality assurance modules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.